| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
The compound is an inhibitor of 5alpha-reductase activity, the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT). It also inhibits the binding of the 5alpha-DHT ligand to its receptor protein, thus acting as a dual inhibitor of the androgen signaling pathway.
|
|---|---|
| ln Vitro |
The primary in vitro activity is the inhibition of 5alpha-reductase. In cell-free assays using rat or human prostate homogenates containing the enzyme, the compound blocks the conversion of [14C]-testosterone to [14C]-DHT. In cell-based assays using dermal papilla cells, it prevents 5alpha-DHT from binding to the androgen receptor, reducing androgen-driven gene expression.
|
| ln Vivo |
In vivo, the compound is used as an active ingredient in cosmetic research formulations applied topically to the skin. It has shown potential for treating acne (by reducing sebum production) and promoting hair growth (by inhibiting the follicular miniaturization caused by DHT) in animal models of androgenetic alopecia.
|
| Enzyme Assay |
A radioligand binding assay is used to study receptor inhibition. The 5alpha-DHT receptor protein is incubated with 3H-labeled 5alpha-DHT in the presence or absence of the test compound. The mixture is filtered, and the retained radioactivity is counted. The compound‘s ability to displace the radioactive ligand is quantified, indicating its binding inhibition potency.
|
| Cell Assay |
An enzymatic assay for 5alpha-reductase is conducted. Rat prostate microsomes (source of the enzyme) are incubated with [14C]-testosterone, NADPH, and varying concentrations of the compound in buffer for 30-60 minutes at 37degC. The reaction is stopped and steroids extracted with organic solvent. The products (testosterone and DHT) are separated by thin-layer chromatography (TLC), and the conversion rate is calculated.
|
| Animal Protocol |
An animal model for hair growth is the C3H mouse, which undergoes androgenetic alopecia. The compound is formulated in a topical vehicle (e.g., ethanol/propylene glycol) and applied once daily to the shaved back skin of mice for 4-8 weeks. Hair growth is assessed by visual scoring and measuring hair follicle density and anagen/telogen ratio from skin biopsies collected at the end of the study.
|
| ADME/Pharmacokinetics |
As a DHEA intermediate and topical cosmetic research ingredient, systemic absorption is low. Applied topically, it is expected to remain primarily in the skin layers. If absorbed, the compound would likely be metabolized by liver enzymes (Phase I and II metabolism) into conjugated steroids and excreted in urine. Its half-life is not reported.
|
| Toxicity/Toxicokinetics |
Topical application of this compound is generally considered safe for cosmetic research purposes. It is not intended for systemic use. There is no reported acute dermal toxicity or skin irritation at recommended concentrations. However, as a steroid derivative, chronic high-dose systemic exposure could potentially cause endocrine disruption.
|
| References |
[1]. Atsushi Kino, et al. Cosmetic. JP60136505A.
|
| Additional Infomation |
The compound (MW: 330.46) serves a dual purpose: as a key synthetic intermediate for producing the adrenal steroid DHEA, and as a topical active ingredient in non-clinical cosmetic research for acne and hair loss. It is not approved as a drug by the FDA for any therapeutic indication.
|
| Molecular Formula |
C21H30O3
|
|---|---|
| Molecular Weight |
330.46
|
| Exact Mass |
330.219
|
| CAS # |
1044-89-9
|
| PubChem CID |
14974601
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4.261
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
24
|
| Complexity |
602
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1C([H])([H])C([H])([H])OC21C([H])([H])C([H])([H])[C@]1([H])[C@]3([H])C([H])([H])C([H])([H])C4=C([H])C(C([H])([H])C([H])([H])[C@]4(C([H])([H])[H])[C@]3([H])C([H])([H])C([H])([H])[C@@]12C([H])([H])[H])=O
|
| InChi Key |
KFDWIKRQOPJCDM-DEPCRRQNSA-N
|
| InChi Code |
InChI=1S/C21H30O3/c1-19-8-5-15(22)13-14(19)3-4-16-17(19)6-9-20(2)18(16)7-10-21(20)23-11-12-24-21/h13,16-18H,3-12H2,1-2H3/t16-,17+,18+,19+,20+/m1/s1
|
| Chemical Name |
(8'R,9'S,10'R,13'S,14'S)-10',13'-dimethylspiro[1,3-dioxolane-2,17'-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-3'-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (30.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (3.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0261 mL | 15.1304 mL | 30.2608 mL | |
| 5 mM | 0.6052 mL | 3.0261 mL | 6.0522 mL | |
| 10 mM | 0.3026 mL | 1.5130 mL | 3.0261 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
